NMTC - NeuroOne Medical Technologies Corp Stock Price, Fair Value and News

1.11USD+0.06 (+5.71%)Market Closed

Market Summary

USD1.11+0.06

Market Closed

5.71%

NMTC Stock Price

View Fullscreen

NMTC RSI Chart

NMTC Valuation

Market Cap

30.5M

Price/Earnings (Trailing)

-2.39

Price/Sales (Trailing)

13.05

EV/EBITDA

-2.24

Price/Free Cashflow

-2.53

NMTC Price/Sales (Trailing)

NMTC Profitability

Operating Margin

-12.47%

EBT Margin

-547.01%

Return on Equity

-332.19%

Return on Assets

-237.33%

Free Cashflow Yield

-39.59%

NMTC Fundamentals

NMTC Revenue

Revenue (TTM)

2.3M

Rev. Growth (Yr)

195.45%

Rev. Growth (Qtr)

176.98%

NMTC Earnings

Earnings (TTM)

-12.8M

Earnings Growth (Yr)

18.95%

Earnings Growth (Qtr)

14.64%

Breaking Down NMTC Revenue

Last 7 days

-0.9%

Last 30 days

-5.1%

Last 90 days

7.8%

Trailing 12 Months

-9.8%

How does NMTC drawdown profile look like?

NMTC Financial Health

Current Ratio

3.06

NMTC Investor Care

Shares Dilution (1Y)

56.68%

Diluted EPS (TTM)

-0.58

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.3M	0	0	0
2023	1.3M	1.9M	2.4M	0
2022	28.8K	100.0K	171.2K	733.0K
2021	1.0M	567.2K	114.0K	48.9K
2020	0	0	1.9M	1.5M
2014	1.6M	0	0	0
2013	331.1K	650.2K	969.3K	1.3M
2012	0	0	0	12.0K
2011	0	0	0	5.4K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of NeuroOne Medical Technologies Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 30, 2024	mertens steve	sold (taxes)	-284	1.13	-252	chief technology officer
Apr 30, 2024	christianson mark	sold (taxes)	-101	1.13	-90.00	business development director
Apr 30, 2024	rosa david a	sold (taxes)	-2,530	1.13	-2,239	ceo and president
Apr 21, 2024	mertens steve	sold (taxes)	-8,337	1.15	-7,250	chief technology officer
Apr 21, 2024	christianson mark	sold (taxes)	-2,334	1.15	-2,030	business development director
Apr 21, 2024	rosa david a	sold (taxes)	-22,623	1.15	-19,673	ceo and president
Mar 31, 2024	mertens steve	sold (taxes)	-302	1.2	-252	chief technology officer
Mar 31, 2024	christianson mark	sold (taxes)	-108	1.2	-90.00	business development director
Mar 31, 2024	rosa david a	sold (taxes)	-2,686	1.2	-2,239	ceo and president
Feb 29, 2024	rosa david a	sold (taxes)	-2,709	1.21	-2,239	ceo and president

Which funds bought or sold NMTC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	AWM Investment Company, Inc.	unchanged	-	-550,999	1,740,000	0.23%
May 15, 2024	STATE STREET CORP	unchanged	-	-19,607	61,919	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-48.00	-	-%
May 15, 2024	Nemes Rush Group LLC	unchanged	-	-165	520	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	36.31	286	8,402	-%
May 15, 2024	Nantahala Capital Management, LLC	reduced	-50.63	-2,397,840	1,438,690	0.08%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	13,572	13,572	-%
May 14, 2024	NORTHERN TRUST CORP	unchanged	-	-11,507	36,337	-%
May 13, 2024	UBS Group AG	reduced	-94.27	-2,849	130	-%
May 13, 2024	Mayo Clinic	unchanged	-	-69,066	218,105	3.55%

Are Funds Buying or Selling NMTC?

Are funds buying NMTC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NMTC

No. of Funds

Unveiling NeuroOne Medical Technologies Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	nantahala capital management, llc	5.1%	1,214,094	SC 13G
Jan 11, 2024	lytton laurence w	5.2%	1,304,102	SC 13G
Aug 02, 2023	manchester management co llc	999%	2,364,052	SC 13G/A

Recent SEC filings of NeuroOne Medical Technologies Corp

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to NeuroOne Medical Technologies Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

NeuroOne Medical Technologies Corp News

Latest updates

NeuroOne Medical Technologies Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2014Q1	2013Q4	2013Q3	2013Q2	2013Q1	2012Q4	2011Q4
Revenue	177.0%	1,377,294	497,253	-	466,176	1,455,188	970,125	485,063	-	6,374	4,974	17,451	20,113	71,474	-	-	-	-	-	-	-	297
Cost Of Revenue	80.0%	986,875	548,125	386,240	434,673	126,886	83,850	38,462	72,807	46,844	65,466	61,935	39,363	109,131	-	-	-	-	-	-	-	-
Gross Profit	101.6%	390,419	193,655	243,666	31,503	-12,307	-15,062	-6,413	-36,223	-13,096	-17,130	-21,839	-21,123	-37,657	-	165	140	252	451	406	360	-
Operating Expenses	-2.4%	3,276,517	3,358,399	3,753,901	3,527,422	3,227,233	3,327,632	2,755,021	3,023,587	2,802,603	2,631,967	3,030,608	2,394,681	2,128,018	2,043,991	-	-	-	-	-	-	-
S&GA Expenses	26.8%	2,002,949	1,579,035	1,862,389	1,821,108	1,663,737	1,889,398	1,529,670	1,818,207	1,742,141	1,623,680	2,129,474	1,313,252	1,193,860	1,259,275	-	-	-	-	-	-	-
R&D Expenses	-28.4%	1,273,568	1,779,364	1,891,512	1,706,314	1,563,496	1,438,234	1,225,351	1,205,380	1,060,462	1,008,287	901,134	1,081,429	934,158	784,716	-	-	-	-	-	-	-
EBITDA Margin	-11.4%	-5.37	-4.82	-5.35	-7.14	-11.99	-57.71	-114	-385	-204	33.63	6.60	-5.05	-2.79	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	6,106	-	-	-3,053	-77,811	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	8.9%	-2,855,090	-3,135,121	-3,468,773	-3,522,828	-1,732,769	-1,374,344	-2,759,727	-3,058,067	-2,807,475	-	-2,951,609	-2,393,916	-1,959,480	11,055,921	-	-	-	-	-	-	-
EBT Margin	-11.6%	-5.47	-4.90	-5.44	-7.25	-12.18	-58.42	-115	-389	-206	32.90	6.61	-0.38	0.45	-	-	-	-	-	-	-	-
Net Income	8.9%	-2,855,090	-3,135,121	-3,468,773	-3,522,828	-1,732,769	-1,374,344	-2,759,727	-3,058,067	-2,807,475	-2,643,163	-2,951,609	-2,393,916	-1,959,480	-566,392	-	-	-	-	-	-	-
Net Income Margin	-11.6%	-5.47	-4.90	-5.44	-7.25	-12.18	-58.42	-112	-397	-220	-87.26	-13.88	-11.77	-7.44	-	-	-	-	-	-	-	-
Free Cashflow	25.5%	-2,206,523	-2,960,446	-3,079,550	-3,727,230	-3,503,765	951,635	-2,690,858	-3,314,910	-2,740,627	-2,064,415	-2,319,329	-2,436,229	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-7.3%	5,395	5,822	8,097	5,758	7,205	9,660	12,823	11,571	14,089	17,183	7,938	9,809	11,917	7,913	4,760	4,462	1,389	2,659	533	1,536	2,575
Current Assets	-7.5%	4,710	5,093	7,313	4,879	6,357	8,967	12,176	10,929	13,443	16,576	7,292	9,271	11,355	7,340	4,155	3,904	829	2,092	302	1,299	2,385
Cash Equivalents	-9.2%	2,435	2,681	5,322	3,083	3,602	4,667	8,160	10,178	12,869	16,184	6,901	8,991	11,274	7,129	4,036	3,824	747	2,044	261	1,247	2,305
Inventory	-18.5%	1,312	1,609	1,727	1,517	1,174	904	705	454	222	229	98.00	52.00	-	14.00	-	-	-	-	-	-	-
Net PPE	-1.8%	496	505	526	587	523	335	354	315	287	217	223	156	161	153	166	101	85.00	68.00	52.00	53.00	-
Liabilities	9.7%	1,540	1,404	1,848	1,837	1,672	1,488	3,218	952	966	1,236	1,385	954	1,057	6,505	2,694	8,389	6,574	7,271	1,770	1,809	2,130
Current Liabilities	11.4%	1,540	1,383	1,793	1,748	1,550	1,335	3,099	815	810	1,062	1,182	747	750	6,183	2,356	8,037	6,290	6,973	1,770	1,809	2,130
Short Term Borrowings	-	122	-	129	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	229
Shareholder's Equity	-12.8%	3,854	4,418	6,249	3,921	5,533	8,172	9,604	10,618	13,122	15,948	6,554	8,855	10,860	1,408	2,066	-	-	-	-	-	445
Retained Earnings	-4.3%	-68,900	-66,031	-62,686	-59,551	-56,100	-52,559	-50,826	-49,452	-46,692	-43,634	-40,827	-38,184	-35,232	-32,838	-30,879	-30,312	-23,221	-21,875	-17,238	-15,885	-14,022
Additional Paid-In Capital	3.3%	72,714	70,425	68,912	63,455	61,598	60,715	60,415	60,055	59,775	59,542	47,369	47,003	46,057	34,224	32,923	26,368	18,022	17,250	15,988	15,599	14,454
Shares Outstanding	6.0%	26,322	24,831	23,929	17,862	16,888	16,231	16,217	15,928	15,795	15,408	12,010	10,269	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	24,808	-	-	-	17,000	-	-	-	82,500	-	-	-	17,100	-	-	-	37,700

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	42.9%	-2,175	-3,809	-2,902	-2,940	-3,551	-3,492	1,018	-2,636	-3,221	-2,679	-2,029	-2,289	-2,379	-1,904	273	-1,222	-1,250	-1,224	-1,142	-1,676	-1,876
Share Based Compensation	15.6%	357	309	271	296	238	300	256	256	-	-	-	-	-	-	-	-	-	-	-97.08	232	70.00
Cashflow From Investing	15.5%	-31.36	-37.13	-50.12	861	1,824	15.00	-3,035	-54.23	-93.32	-61.49	-35.11	-29.91	-	-	-56.36	-25.84	-29.95	-10.27	-4.40	-53.95	-
Cashflow From Financing	62.7%	1,960	1,205	5,192	1,561	662	-15.71	-	-	-322*	12,024	-24.98	36.00	6,527	4,997	-3.87	4,325	-16.87	3,019	161	672	3,896
Buy Backs	-16.7%	11.00	14.00	-	-	99.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NMTC Income Statement

2024-03-31

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Product revenue	$ 1,377,294	$ 466,176	$ 2,354,943	$ 580,755
Cost of product revenue	986,875	434,673	1,698,210	561,559
Product gross profit	390,419	31,503	656,733	19,196
Collaborations revenue				1,455,188
Operating expenses:
Selling, general and administrative	2,002,949	1,821,108	4,176,421	3,484,845
Research and development	1,273,568	1,706,314	2,756,885	3,269,810
Total operating expenses	3,276,517	3,527,422	6,933,306	6,754,655
Loss from operations	(2,886,098)	(3,495,919)	(6,276,573)	(5,280,271)
Other income (expense), net	31,008	(26,909)	76,583	24,674
Loss before income taxes	(2,855,090)	(3,522,828)	(6,199,990)	(5,255,597)
Provision for income taxes
Net loss	$ (2,855,090)	$ (3,522,828)	$ (6,199,990)	$ (5,255,597)
Net loss per share:
Basic (in Dollars per share)	$ (0.11)	$ (0.21)	$ (0.25)	$ (0.32)
Number of shares used in per share calculations:
Basic (in Shares)	25,910,478	16,414,795	24,947,813	16,321,891

NMTC Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 2,434,655	$ 5,322,493
Accounts receivable	555,639
Inventory	1,311,673	1,726,686
Prepaid expenses	407,777	263,746
Total current assets	4,709,744	7,312,925
Intangible assets, net	78,419	89,577
Right-of-use assets	110,724	169,059
Property and equipment, net	496,015	525,753
Total assets	5,394,902	8,097,314
Current liabilities:
Accounts payable	780,839	685,104
Accrued expenses and other liabilities	759,620	1,107,522
Total current liabilities	1,540,459	1,792,626
Operating lease liability, long term		55,284
Total liabilities	1,540,459	1,847,910
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding.
Common stock, $0.001 par value; 100,000,000 shares authorized; 26,321,750 and 23,928,945 shares issued and outstanding as of March 31, 2024 and September 30, 2023, respectively.	26,322	23,929
Additional paid–in capital	72,714,414	68,911,778
Accumulated deficit	(68,886,293)	(62,686,303)
Total stockholders’ equity	3,854,443	6,249,404
Total liabilities and stockholders’ equity	$ 5,394,902	$ 8,097,314

About NeuroOne Medical Technologies Corp

NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

CEO	Mr. David A. Rosa M.D.
WEBSITE	n1mtc.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	15

NeuroOne Medical Technologies Corp Frequently Asked Questions

What is the ticker symbol for NeuroOne Medical Technologies Corp? What does NMTC stand for in stocks?

NMTC is the stock ticker symbol of NeuroOne Medical Technologies Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NeuroOne Medical Technologies Corp (NMTC)?

As of Fri May 17 2024, market cap of NeuroOne Medical Technologies Corp is 30.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NMTC stock?

You can check NMTC's fair value in chart for subscribers.

What is the fair value of NMTC stock?

You can check NMTC's fair value in chart for subscribers. The fair value of NeuroOne Medical Technologies Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of NeuroOne Medical Technologies Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NMTC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is NeuroOne Medical Technologies Corp a good stock to buy?

The fair value guage provides a quick view whether NMTC is over valued or under valued. Whether NeuroOne Medical Technologies Corp is cheap or expensive depends on the assumptions which impact NeuroOne Medical Technologies Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NMTC.

What is NeuroOne Medical Technologies Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, NMTC's PE ratio (Price to Earnings) is -2.39 and Price to Sales (PS) ratio is 13.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NMTC PE ratio will change depending on the future growth rate expectations of investors.